APA (7th ed.) Citation

Chen, X., Wang, K., Liao, Y., Zheng, C., Yang, D., Li, Z., & Zhai, L. (2025). Safety and efficacy of rechallenge with immune checkpoint inhibitors and anlotinib in advanced non-small cell lung cancer without targetable driver mutations. BMC Cancer, 25(1), 1. https://doi.org/10.1186/s12885-025-14209-6

Chicago Style (17th ed.) Citation

Chen, Xinrong, Ke Wang, Yongxin Liao, Chuangjie Zheng, Deyu Yang, Zhichao Li, and Linzhu Zhai. "Safety and Efficacy of Rechallenge with Immune Checkpoint Inhibitors and Anlotinib in Advanced Non-small Cell Lung Cancer Without Targetable Driver Mutations." BMC Cancer 25, no. 1 (2025): 1. https://doi.org/10.1186/s12885-025-14209-6.

MLA (9th ed.) Citation

Chen, Xinrong, et al. "Safety and Efficacy of Rechallenge with Immune Checkpoint Inhibitors and Anlotinib in Advanced Non-small Cell Lung Cancer Without Targetable Driver Mutations." BMC Cancer, vol. 25, no. 1, 2025, p. 1, https://doi.org/10.1186/s12885-025-14209-6.